Yazar "Uygunoglu U." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Characteristics of optic neuropathy in Behçet disease
    (Lippincott Williams and Wilkins, 2018) Akdal G.; Toydemir H.E.; Saatci A.O.; Uygunoglu U.; Altunrende B.; Saip S.; Yaman A.; Keskino P.; Yılmaz S.G.; Çelebisoy N.; Bajin M.S.; Siva A.; Akman-Demir G.
    Objective: We present the clinical profile, features, and neuroimaging findings of 25 patients with Behçet disease (BD), and optic neuropathy (ON), which has been rarely reported in BD. Methods: Data from 5 university hospitals were retrospectively reviewed, and patients with BD and ON were evaluated. There were 2 groups: (1) those already diagnosed with BD when ON developed (BD›ON group) and (2) those diagnosed with BD during the evaluation of ON (ON›BD group). Results: There were 25 BD patients with ON (13 males). Among these, 13 had ON›BD, and 12 had BD›ON. Seventeen patients had unilateral ON, and 7 patients had recurrent ON. BD›ON patients were older. Disc edema was seen more in ON›BD than in BD›ON patients (10 vs 3). Fourteen patients also had uveitis, 7 with BD›ON and 7 with ON›BD. There was other neurologic involvement in 8 patients; in the BD›ON group, 4/4 had MS-like disease, in the ON›BD group, 3 had typical parenchymal BD, and 1 had MS-like disease. Twenty of 21 patients received immunosuppressive medications, corticosteroids, or both. Prognosis was favorable in most: vision improved in 20 patients, more often in those receiving combined therapies. Conclusion: BD may be diagnosed earlier if it is considered and investigated during the assessment of ON, particularly in high-risk regions. Prognosis of ON related to BD seems to be favorable. Immunosuppressants should be given along with corticosteroids. MS-like presentations should also be kept in mind in patients with BD and ON. Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
  • Küçük Resim Yok
    Öğe
    Neuromyelitis optica and neuromyelitis optica spectrum disorder patients in Turkish cohort demographic, clinical, and laboratory features
    (Lippincott Williams and Wilkins, 2015) Altintas A.; Karabudak R.; Balca B.P.; Terzi M.; Soysal A.; Saip S.; Kurne A.T.; Uygunoglu U.; Nalbantoglu M.; Celik G.G.; Isik N.; Celik Y.; Gokcay F.; Duman T.; Boz C.; Yucesan C.; Mangan M.S.; Celebisoy N.; Diker S.; Isikay I.C.; Kansu T.; Siva A.
    Background: Neuromyelitis optica (NMO) is an immune-mediated, chronic relapsing, inflammatory disease characterized by severe attacks of optic neuritis and myelitis. Objective: To determine the demographic, clinical, and laboratory features; antibody status; and treatment modalities of patients with NMO and neuromyelitis optica spectrum disorders in a Turkish cohort from 11 centers. Methods: A total of 182 patients were included in this study. Data on age at disease onset, sex, type of attacks, clinical presentation, analysis of cerebrospinal fluid, serum antiaquaporin-4 antibody status, annual progression index, and medical and family histories were collected. Results: Mean age was 38.43 ± 12.40 years (range, 13 to 75 y), and mean age at disease onset was 31.29 ± 12.40 years (median, 29 y; range, 10 to 74 y). In NMO group, the rate of NMO immunoglobulin (Ig)G positivity was 62.5%. The annual progression index was significantly higher in the longitudinally extending spinal cord lesion. The mean Expanded Disability Status Scale score was higher in the late than early-onset NMO group. Conclusion: Our results revealed a lower rate of NMO IgG positivity, more severe disability in patients with NMO/neuromyelitis optica spectrum disorders presenting with either transverse myelitis or lateonset NMO, and no correlation between disability and NMO IgG status. © 2015 Wolters Kluwer Health, Inc. All rights reserved.